Project Grant R01CA291761
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$773K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Cancer Institute
Federal Grant Program
93.077
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This Project Grant award of $622,957 from the National Institutes of Health (NIH) Office of the Director, under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077), supports research by Duke University to investigate the chemical composition and behavioral effects of novel tobacco products, including oral nicotine pouches and "non-menthol" cigarettes. The study aims to analyze the flavors, sweeteners, and nicotine forms in these products, and...
This Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) will provide $661,139 to The Ohio State University to test the use of oral nicotine pouches as an alternative to cigarette smoking among rural Appalachian adults. The study will evaluate whether oral nicotine pouches are more effective than nicotine replacement therapy (NRT) in helping this population reduce or quit smoking, which contributes to high cancer rates in the region. The...
This Project Grant award from the National Institutes of Health (NIH) under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) provides $1,197,896 to the University of Oklahoma Health Sciences Center to conduct a longitudinal study examining the impact of electronic nicotine delivery system (ENDS) product characteristics on use behaviors and abuse liability among young adults. The study will utilize a combination of traditional survey methods and...
The federal Project Grant award R01CA298165 was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The $625,201 award will fund a 5-year randomized factorial trial to evaluate the combined impact of varenicline, nicotine lozenges, and a smartphone-based medication adherence intervention on smoking cessation outcomes among 496 adult daily smokers. The study aims to improve smoking cessation treatment and reduce cancer risk. A...
The National Institutes of Health (NIH) awarded a 5-year, $370,000 Project Grant under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) to the Marshall University Research Corporation (MURC) to determine the impact of synthetic coolants on nicotine's abuse liability and initiation-related behaviors. The research will utilize a novel vapor self-administration assay in mice to examine how synthetic coolants, which are increasingly used in vaping...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under CFDA 93.077 Family Smoking Prevention and Tobacco Control Act Regulatory Research program provides $3,230,000 to The Regents of the University of California, San Francisco (UCSF) to investigate the cardiovascular effects of dual use of tobacco and nicotine delivery products like cigarettes and e-cigarettes. The project aims to (1) understand the cardiovascular health effects of dual use...
The National Institutes of Health (NIH), through the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077), awarded a $669,321 project grant to the Regents of the University of California at Riverside (UC Riverside). The grant supports a 1-year study to characterize new and emerging ingredients, acids, toxicants, and indicators of non-tobacco nicotine in electronic cigarette (e-cigarette) products. The research will involve: Analyzing 600 commercial...
This Project Grant award, totaling $3,257,011, was provided by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279). The award will fund a hybrid effectiveness-implementation randomized controlled trial to evaluate the impact of switching to electronic nicotine delivery systems (ENDS) compared to nicotine replacement therapy (NRT) for smoking cessation among clients enrolled in substance use disorder (SUD) treatment programs in...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $395,566 to Flik Therapeutics, Inc. to support the development of a novel FDA-regulated pharmacotherapy and multimodal nicotine cessation program. The goal is to create a more effective smoking cessation therapy compared to the current standard of care, which has low success rates. This Phase I proposal will fund the initial development of the...
This federal Project Grant award, valued at $723,676 and awarded by the National Institute on Drug Abuse (NIDA) under CFDA program 93.279 "Drug Use and Addiction Research Programs", supports research to investigate the long-term effects of electronic cigarettes (e-cigarettes) on brain health. The grant will fund a study comparing brain and physiological measures between former smokers who switched to e-cigarettes and those who quit smoking entirely. The research aims to shed light on...